CSPC Secures US$25.00 Million R&D Milestone from AstraZeneca in Long-Acting Peptide Collaboration

Bulletin Express

Jul 10

CSPC Pharmaceutical Group Limited (CSPC) announced receipt of a US$25.00 million research and development milestone payment from AstraZeneca on 10 July 2026.

The payment arises from the strategic collaboration and licence agreement signed on 30 January 2026, which combines CSPC’s proprietary sustained-release delivery and AI-driven peptide discovery platforms with AstraZeneca’s global development and commercial capabilities. An upfront payment was previously received on 29 May 2026.

Management stated that achievement of this milestone confirms that development activities for the licensed long-acting peptide medicines are advancing in line with plan.

The companies will continue joint development, manufacturing and commercialisation efforts, although CSPC cautions that project outcomes remain subject to customary R&D uncertainties. Further material updates related to the agreement will be disclosed as appropriate.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/1123700250"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1123700250\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1123700250?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-10 22:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1123700250","market":"hk","top_or_hot":-1,"title":"CSPC Secures US$25.00 Million R&D Milestone from AstraZeneca in Long-Acting Peptide Collaboration","media":"Bulletin Express","content":"<p>CSPC Pharmaceutical Group Limited (CSPC) announced receipt of a US$25.00 million research and development milestone payment from AstraZeneca on 10 July 2026.</p>\n<p>The payment arises from the strategic collaboration and licence agreement signed on 30 January 2026, which combines CSPC’s proprietary sustained-release delivery and AI-driven peptide discovery platforms with AstraZeneca’s global development and commercial capabilities. An upfront payment was previously received on 29 May 2026.</p>\n<p>Management stated that achievement of this milestone confirms that development activities for the licensed long-acting peptide medicines are advancing in line with plan.</p>\n<p>The companies will continue joint development, manufacturing and commercialisation efforts, although CSPC cautions that project outcomes remain subject to customary R&D uncertainties. Further material updates related to the agreement will be disclosed as appropriate.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CSPC Secures US$25.00 Million R&D Milestone from AstraZeneca in Long-Acting Peptide Collaboration</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCSPC Secures US$25.00 Million R&D Milestone from AstraZeneca in Long-Acting Peptide Collaboration\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-07-10 22:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CSPC Pharmaceutical Group Limited (CSPC) announced receipt of a US$25.00 million research and development milestone payment from AstraZeneca on 10 July 2026.</p>\n<p>The payment arises from the strategic collaboration and licence agreement signed on 30 January 2026, which combines CSPC’s proprietary sustained-release delivery and AI-driven peptide discovery platforms with AstraZeneca’s global development and commercial capabilities. An upfront payment was previously received on 29 May 2026.</p>\n<p>Management stated that achievement of this milestone confirms that development activities for the licensed long-acting peptide medicines are advancing in line with plan.</p>\n<p>The companies will continue joint development, manufacturing and commercialisation efforts, although CSPC cautions that project outcomes remain subject to customary R&D uncertainties. Further material updates related to the agreement will be disclosed as appropriate.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01093","symbol_name":"石药集团","start_time":0,"source_url":"","article_id":"1123700250","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1123700250","pubTimestamp":1783694548,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"CSPC Pharmaceutical Group Limited (CSPC) announced receipt of a US$25.00 million research and development milestone payment from AstraZeneca on 10 July 2026. The payment arises from the strategic...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01093":"石药集团"},"translate_title":"石药集团从阿斯利康获得2500万美元长效肽合作研发里程碑","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01093":1},"content_text":"CSPC Pharmaceutical Group Limited (CSPC) announced receipt of a US$25.00 million research and development milestone payment from AstraZeneca on 10 July 2026.\nThe payment arises from the strategic collaboration and licence agreement signed on 30 January 2026, which combines CSPC’s proprietary sustained-release delivery and AI-driven peptide discovery platforms with AstraZeneca’s global development and commercial capabilities. An upfront payment was previously received on 29 May 2026.\nManagement stated that achievement of this milestone confirms that development activities for the licensed long-acting peptide medicines are advancing in line with plan.\nThe companies will continue joint development, manufacturing and commercialisation efforts, although CSPC cautions that project outcomes remain subject to customary R&D uncertainties. Further material updates related to the agreement will be disclosed as appropriate.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}